Terms: = Breast cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
899 results:
1. Neuropilin-1-Targeted Nanomedicine for Spatiotemporal Tumor Suppression through Photodynamic Vascular Damage and Antiangiogenesis.
Li XY; Yan N; Wu YY; Kong RJ; Qiu ZW; Liu SP; Wu DH; Cheng H
ACS Appl Mater Interfaces; 2024 May; 16(17):21709-21721. PubMed ID: 38651381
[TBL] [Abstract] [Full Text] [Related]
2. Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes.
Thangavel SK; Mohamed Kasim MS; Rengan R
Inorg Chem; 2024 Apr; 63(16):7520-7539. PubMed ID: 38590210
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of NF-κB-Mediated Proinflammatory Transcription by Ru(II) Complexes of Anti-Angiogenic Ligands in Triple-Negative breast cancer.
Chakraborty A; Ghosh S; Chakraborty MP; Mukherjee S; Roy SS; Das R; Acharya M; Mukherjee A
J Med Chem; 2024 Apr; 67(7):5902-5923. PubMed ID: 38520399
[TBL] [Abstract] [Full Text] [Related]
4. Recent development of vegfr small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract] [Full Text] [Related]
5. Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
Mäenpää N; Tiainen L; Hämäläinen M; Luukkaala T; Tanner M; Lahdenperä O; Vihinen P; Karihtala P; Kellokumpu-Lehtinen PL; Moilanen E; Jukkola A
BMC Cancer; 2024 Mar; 24(1):331. PubMed ID: 38468231
[TBL] [Abstract] [Full Text] [Related]
6. EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer.
Li Z; Liu Q; Cai Y; Ye N; He Z; Yao Y; Ding Y; Wang P; Qi C; Zheng L; Wang L; Zhou J; Zhang QQ
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167114. PubMed ID: 38447883
[TBL] [Abstract] [Full Text] [Related]
7. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/vegfr Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Hu Y; Narayan A; Xu Y; Wolfe J; Vu D; Trinh T; Kantak C; Ivy SP; Eder JP; Deng Y; LoRusso P; Kim JW; Patel AA
JCO Precis Oncol; 2024 Feb; 8():e2300289. PubMed ID: 38412387
[TBL] [Abstract] [Full Text] [Related]
8. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential vegfr-2 inhibitors, apoptotic inducers.
Elgammal WE; Halawa AH; Eissa IH; Elkady H; Metwaly AM; Hassan SM; El-Agrody AM
Bioorg Chem; 2024 Apr; 145():107157. PubMed ID: 38340473
[TBL] [Abstract] [Full Text] [Related]
9. ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin β3-vegfr2 interaction.
Benedetti A; Turco C; Gallo E; Daralioti T; Sacconi A; Pulito C; Donzelli S; Tito C; Dragonetti M; Perracchio L; Blandino G; Fazi F; Fontemaggi G
Cell Death Dis; 2024 Feb; 15(2):113. PubMed ID: 38321003
[TBL] [Abstract] [Full Text] [Related]
10. Development of Novel Indazolyl-Acyl Hydrazones as Antioxidant and Anticancer Agents that Target vegfr-2 in Human breast cancer Cells.
Parameshwaraiah SM; Shivakumar R; Xi Z; Siddappa TP; Ravish A; Mohan A; Poonacha LK; Uppar PM; Basappa S; Dukanya D; Gaonkar SL; Kemparaju K; Lobie PE; Pandey V; Basappa B
Chem Biodivers; 2024 Mar; 21(3):e202301950. PubMed ID: 38258537
[TBL] [Abstract] [Full Text] [Related]
11. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.
Fang Y; Zhang Q; Chen Z; Guo C; Wu J
Aging (Albany NY); 2024 Jan; 16(1):322-347. PubMed ID: 38189813
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Mechanism Analysis of Protopine Against Triple Negative breast cancer.
Chen T; Jiang H; Hu G; Acma FM; Huang B
Stud Health Technol Inform; 2023 Nov; 308():480-486. PubMed ID: 38007774
[TBL] [Abstract] [Full Text] [Related]
13. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a vegfr inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
[TBL] [Abstract] [Full Text] [Related]
14. Exploration of antiproliferative potential of modified triazole-benzohydrazone scaffold: Multitarget approach.
Ali AM; Khalaf MA; Bhongade BA; Selim KB; Mostafa AS
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300383. PubMed ID: 37946599
[TBL] [Abstract] [Full Text] [Related]
15. (E)-2-Methoxy-4-(3-(4-Methoxyphenyl) Prop-1-en-1-yl) Phenol Suppresses breast cancer Progression by Dual-Regulating vegfr2 and PPARγ.
Kim NY; Park HM; Lee HP; Hong JT; Yoon DY
J Microbiol Biotechnol; 2024 Feb; 34(2):240-248. PubMed ID: 37942548
[TBL] [Abstract] [Full Text] [Related]
16. Structure and activity relationship analysis of xanthones from mangosteen: Identifying garcinone E as a potent dual EGFR and vegfr2 inhibitor.
Li J; Nie X; Panthakarn Rangsinth ; Wu X; Zheng C; Cheng Y; Shiu PH; Li R; Lee SM; Fu C; Zhang J; Leung GP
Phytomedicine; 2024 Jan; 122():155140. PubMed ID: 37939410
[TBL] [Abstract] [Full Text] [Related]
17. 5α-Hydroxycostic acid inhibits choroidal neovascularization in rats through a dual signalling pathway mediated by VEGF and angiopoietin 2.
Lei W; Xu H; Yao H; Li L; Wang M; Zhou X; Liu X
Mol Med; 2023 Nov; 29(1):151. PubMed ID: 37914992
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
19. Antitumor activity of the new tyrphostin briva against BRAF
Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B
Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738
[TBL] [Abstract] [Full Text] [Related]
20. Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, vegfr-2 inhibition, apoptosis induction and migration inhibition studies.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk BA; Husein DZ; Asmaey MA; Ibrahim IM; Metwaly AM
Pathol Res Pract; 2023 Nov; 251():154894. PubMed ID: 37857034
[TBL] [Abstract] [Full Text] [Related]
[Next]
